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Abstract: The good outcome of hematopoietic stem cell (HSC) transplantation is hampered by low doses of CD34+ cell
infusion. Transplanted HSCs undergo a replicative stress that causes accelerated senescence due to rapid telomere shortening.
The expansion of human cord blood HSCs is instrumental in obtaining a large number of "good quality" cells, in terms of
telomere length and telomerase activity compared to adult HSCs. 
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Introduction
Tissue-specific stem cells, like most somatic stem cells,
possess the unique ability of self-renewal and multili-
neage differentiation. These combined properties are
reflected in the ability of hematopoietic stem cells
(HSCs) to completely and durably reconstitute hemato-
poiesis of a myeloablated recipient and maintain it
throughout the entire life span [13, 19]. HSC self-rene-
wal is not a perfect process and daughter cells have
progressively reduced proliferative capacity, due in part
to progressive telomere erosion at each cell division.
This, in turn, leads to proliferative senescence that can
be observed both in vivo and in vitro. Telomeres are
structures at the end of eukaryotic chromosomes that
protect chromosomes from degradation, fusion, and re-
combination. In mammalian cells, they consist of hexa-
nucleotide (TTAGGG) repeats and several associated
protein components. In the absence of compensatory
mechanisms, dividing cells undergo gradual telomere
erosion. When telomeres reach a critical degree of shor-
tening, cells recognize this as DNA damage and initiate
pro-apoptotic programs or enter senescence [10]. 
The best-characterized compensatory mechanism for
maintenance of telomere length is mediated by telome-
rase, an enzyme that synthesizes terminal telomere re-
peats [31]. In contrast to normal somatic cells, which are
telomerase-negative, hematopoietic stem cells have low
levels of telomerase, which can be transiently up-regu-
lated upon cytokine stimulation [30]. CD34+ popula-
tions exhibit low telomerase activity, but activity
increases significantly in both HSC and progenitor
populations as cells progress from G0 into S phase [6, 7].
In early studies using cytokine combinations that were
effective in activating stem cells into the cell cycle, but
were less effective in maintaining long-term HSC pro-
liferation, telomerase was up-regulated at early stages of
culture but declined rapidly after 3 to 4 weeks [6, 7]. In
these studies, 1 to 1.5 kb telomeric DNA was lost over
3 to 4 weeks of culture of CD34+ cells from cord blood
(CB), mobilized peripheral blood (MPB), or bone mar-
row (BM). Thus, telomerase activity in HSCs did not
prevent telomere shortening although it may have
limited the extent of telomere degradation. 
After allogenic and autologous transplants, it has
been observed a telomere loss of 1-2 kb (corresponding
to 15-40 years of premature aging) due to the extensive
cell regeneration after infusion [20, 29]. The kinetics of
hemopoietic engraftment impose replicative stress on
the HSC, resulting in a pronounced aging effect, which
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may be sufficient to accelerate the onset of clonal hema-
topoietic disorders usually associated with later life [26,
27]. Moreover, short telomeres may limit the remaining
replicative capacity of cells, measured in term of colony
forming unit (CFU) and long-term culture initiating cells
(LTC-IC) efficiency, and may be responsible for sub-
sequent changes and potential deteriorating effects (such
as acquisition of secondary myelodysplastic syndromes
or acute myeloid leukemia) [26, 27]. Average telomere
lengths were 10.4 kbp, 7.4 kbp, and 7.6 kbp in CB, PB,
and BM CD34+ cells, respectively [6]. Thus, CB HSCs
posses a proliferative advantage of about 3 kbp respect
BM and MPB. If the decrease in telomere length results
purely from increased replicative demand on engrafted
HSC, use of a larger number of repopulating cells with
longer telomeres should be beneficial. The use of CB as
a source of HSCs for allogeneic transplantation has been
limited by the HSC number present in a single harvest,
which limits the utility of this source to pediatric use or
to adults of low body weight [13, 16]. Ex vivo expansion
of neonatal HSCs would be of considerable clinical
utility and preliminary phase 1 results have been re-
ported [12]. 
These findings raise the question if the ex vivo expan-
sion could be able: (1) to maintain reproductive integrity
of the repopulating cells, (2) to induce a not dramatic
shortening of telomeres and (3) to produce a larger
number of primitive precursors and committed progeni-
tors in order to limit the number of HSC divisions after
transplantation.
Ex vivo expansion of CB CD34+ cells
The transplantation assay available in sublethally irradi-
ated non-obese diabetic/severe combined immunodefi-
cient (NOD/SCID) mice has been instrumental in
defining and characterizing the most primitive cells of
the hemopoietic system [14, 23]. The NOD/SCID model
system has been shown to support the engraftment and
retention of primitive human HSCs with the potential for
extensive proliferation and multilineage differentiation
[1, 2, 4, 23, 28]. Unlike the majority of LTC-ICs is
incapable of repopulation, human long-term NOD/SCID
repopulating cells (SRCs) are found exclusively in the
CD34+CD38- cell fraction [1, 28]. Furthermore, kinetic
experiments indicate that engraftment of SRCs is fol-
lowed by a large expansion of LTC-ICs in vivo, sugges-
ting that these are derived from a more primitive cell [2].
Our recent studies [9, 21, 23] have demonstrated the
propagation of CB CD34+ cells for months in different
culture systems, with extensive expansion of stem cells
as measured by Cobbelstone Area-Forming Cell
(CAFC) and LTC-IC assay or NOD/SCID engraftment.
SRCs in CB can be expanded many-fold for up to 10
weeks of culture in the presence of stem cell factor
(SCF), the ligand for c-kit; flt3/flk2 ligand (FL), c-mpl
ligand thrombopoietin (TPO), and interleukin 6 (IL-6)
and sustain the hematopoietic reconstitution over 3 serial
passages in NOD/SCID mice. These systems are criti-
cally dependent on provision of TPO, as a recombinant
factor added twice a week. The stroma-independent
LTC was performed in a continuous manner for 20
weeks or in a fractionated manner stopping it every 4
weeks for the paramagnetic immuno-isolation of CD34+
cells (Fig. 1). The data generated in the stroma-inde-
pendent expansion-isolation procedure (fractionated
cultures) allowed direct evaluation of purified CD34+
cells at monthly intervals. Progenitors (CFCs and granu-
lo-erythro-monocyte-macrophage colony forming
units) continued to expand throughout the 20 weeks of
study, whereas stem cells expanded through week 16 but
then declined sharply by week 20 as measured by in vitro
LTC-IC and in vivo SRC assay. By transplanting limi-
ting dose of CD34+ in mice at different time points we
have demonstrated the expansion of stem cell compart-
ment over 16 weeks of culture measured as large in-
crease in SRCs. In contrast to the CB cultures,
cytokine-stimulated cultures of CD34+ cells from adult
BM or G-CSF MPB did not sustain significant levels of
CD34+ production beyond 4 weeks. 
This result points to the reduced proliferative poten-
tial of adult stem cells versus neonatal stem cells that
may be due to a higher probability of differentiation than
of self-renewal or to a higher frequency of stem cell
apoptosis [9]. 
Ex vivo CB CD34+ cell telomere shortening
and telomerase activity
The ability to maintain HSCs in vitro for prolonged
periods provides a valuable system for evaluating the
role of telomerase in telomere length maintenance and
cell expansion. Because previous studies had indicated
that progressive telomere shortening would be antici-
pated with in vitro expansion [7, 27] comparable to up
to 20 years of normal age-associated telomere loss, we
chose to closely monitor telomerase activity and te-
lomere length in the improved long-term CB cultures
using the cytokine combinations optimal for SRC ex-
pansion. We show that under both these culture condi-
tions, CB CD34+ cells undergo extensive proliferation
and self-renewal for 4 to 5 months with sustained elev-
ation of telomerase activity and without concomitant
significant telomere shortening. Primitive hemato-
poietic precursors as detected by CAFC and by LTC-IC
assays are maintained for up to 16 to 18 weeks and
greatly expand over this time. During this period, re-
populating ability is maintained and the SRC number is
greatly increased. After this period of telomere stabili-
zation (0-16 weeks), telomeric DNA begins to be lost,
coinciding in cytokine-stimulated cultures with a steep
decline in LTC-ICs and SRCs by week 20. Most import-
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Fig. 1. a. Continuous expansion. Schematic representation of continuous stroma-free LTCs with cytokines. In continuous culture, CB CD34+
cells were plated at 5 × 104/mL in triplicate or quadruplicate tissue culture flasks and biweekly supplied with cytokines until week 20.  Every
4 weeks expanded cells was analyzed for LTC-IC and SRC output. b. Fractionated expansion. Schematic representation of fractionated
stroma-free LTCs with cytokines. In fractionated cultures, CB CD34+ cells were plated at 5 × 104/mL in triplicate or quadruplicate tissue
culture flasks. Every 4 weeks all cells were harvested and CD34+ cells were isolated with miniMACS devices, analyzed with LTC-IC and
SRC assays, and then recultured. 
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antly, in these systems this proliferation occurred with-
out significant telomere loss until late stages of culture
and correlated with sustained up-regulation of telomer-
ase in the stem/progenitor compartment of CD34+ cells.
Because telomerase activity is restricted to the CD34+
cells, the dilution by differentiating cells in continuous
cultures underestimated telomerase activity in the
stem/progenitor population by a factor of 5- to 10-fold.
Adjusting for this dilution by factoring in the CFC
content as a measure of these early cells, the stem/pro-
genitor population maintained telomerase activity com-
parable to levels found in immortal tumor cell lines
throughout the culture [7]. Levels were also comparable
to those of hTERT-transduced human fibroblast clones
that showed stable or elongated telomeres despite exten-
sive proliferation [8, 17]. 
In stroma-free cultures of CB CD34+ cells, telomer-
ase levels remained quite high in the first 8 weeks, but
then fell to 25% of input levels between 8 and 16 weeks,
and to 12% by week 20. In adult CD34+ cell cultures, the
telomerase levels of the input cells and of the recovered
CD34+ cells at 1 and 3 weeks were comparable but
significantly lower than in CB cultures over the first 2
months. In the majority of CB cultures, telomeres re-
mained stable for over 3 to 4 months and only at late
stages telomeres begin to shorten. Indeed, in some cul-
tures telomere elongation was noted in the first month.
At week 3, in cytokine-stimulated cultures of adult
CD34+ cells, telomeres of the CD34+ subset were slight-
ly shorter (-0.1 to -0.3 kb) than input telomere length.
The great reduction in CD34+ cell recovery by week 4
precluded telomere measurement of this subset; how-
ever, telomere measurement of unseparated culture cells
at this time showed a loss of 0.7 kb. This contrasted with
the lengthening (+0.9-1.0 kb) seen in CB cultures over
the same time period. The telomerase activity level in
extracted cell protein does not take into account the role
of nuclear localization of the enzyme in determining
biologic activity [16]. 
Nevertheless, stable enzyme up-regulation is the
most plausible explanation for telomere stabilization.
Given a doubling time of 24 hours, then over 20 weeks
the stem cells would have undergone 140 population
doublings (PDs). With the average loss of telomeric
DNA of 50 to 100 bp/PD seen in telomerase-negative
cells, 7 to 17 kb of telomere would have been lost in the
absence of telomerase up-regulation, and cultures would
have terminated because of proliferative senescence.
Even with a more conservative assumption of doubling
every 48 hours, the stem cells would have lost telomere
DNA equivalent to a lifetime of normal telomere ero-
sion. In this regard, the HSCs in late passage CB cultures
would more closely correspond to adult HSCs, with
much reduced expansion potential in vitro, reduced te-
lomerase levels, and loss of capacity to stabilize te-
lomeres [6, 27]. Thus the 20-week culture may span a
developmental stage of transition from fetal/neonatal to
adult stem cell.
Does the in vitro model predict for the in vivo
situation? 
Analysis of age-related changes in granulocyte telomere
length has revealed an average loss of 39 bp/year, but in
the first 6 months of life telomeres shorten at a much
more rapid rate corresponding to 3 kb/year [20]. This
would correspond to 15 to 30 stem cell divisions in the
first 6 months of life, followed by less than one stem cell
division per year [27]. This would not have been pre-
dicted from the in vitro data unless the extent of stem
cell proliferation in the first 6 months was itself biphasic,
with stable telomeres only for the first 3 months fol-
lowed by rapid loss as HSCs transit to adult type while
still actively proliferating. Numerous studies have inves-
tigated telomere shortening, particularly following auto-
logous or allogeneic stem cell transplantation [13, 20,
25, 26, 29]. Although significant telomere shortening is
reported to occur within the first year after transplanta-
tion [25] as yet there is no evidence that this shortening
leads to impaired hematopoiesis in the majority of cases
[5], but there are reports where late graft failure was
associated with significant telomere shortening [26].
Perhaps the most compelling evidence for telomere
length relevance in hematopoietic cells is the recent
demonstration of a highly significant association be-
tween blood leukocyte telomere length and mortality in
a group of healthy elderly individuals [3]. Those with
the shortest telomeres had poorer survival, attributable
in part to higher mortality from heart disease and infec-
tious diseases. The loss in median survival associated
with possession of shorter telomeres in any of the age
cohorts studied was 4.8 years for women and 4.0 years
for men. 
The development of an improved in vitro CB CD34+
culture system that supports a many thousand-fold am-
plification of HSCs has provided insight into the role of
telomerase up-regulation in maintaining telomere sta-
bility in neonatal HSCs. It has also revealed an important
distinction between adult and neonatal HSCs with re-
spect to onset of proliferative senescence. The clinical
potential of our observations are evident because very
extensive expansion of CB HSCs can be obtained over
many months without deterioration of HSC quality as
measured by NOD/SCID engraftment and stable te-
lomeres. Ex vivo expansion can extend the use of CB,
not only to all adult recipients, but potentially to multiple
recipients, without concern that extensive telomere shor-
tening would compromise the long-term survival of the
recipients. Particularly poor results are seen after an
unrelated CB transplant when the nucleated cell dose
infused is less than 1.5×107/kg, or 1.7×105 CD34+
cells/kg [11]. CB harvests are generally sufficient for
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pediatric engraftment (median age 7 years, 25 kg body
weight) and would be approaching the lower limits for
optimal engraftment in adults up to 60 kg with engraft-
ment problems likely in larger individuals. When pa-
tients receive lower cell doses, risk of graft failure is
exceedingly high and time to neutrophil recovery is
prolonged. Furthermore, survival in recipients of one or
2 HLA-mismatched CB transplants is improved with
higher cell doses [11, 24]. A recent study concluded that
raising the nucleated cell dose to approximately
3×107/kg may offset the negative effect of one HLA-
mismatch [11, 24]. CB ex vivo expansion that does not
cause proliferative senescence is an attractive option for
adult unrelated transplantation, also in the cases with one
or two HLA mismatches.
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